image credit- shutterstock
Jiangsu Recbio Technology, a leading Chinese biopharmaceutical company, has entered into a licensing cooperation agreement, and have commenced the technology transfer of their Recombinant 9-valent HPV (HPV9) vaccine, REC603, to Biological E. Limited (BE), a leading Indian vaccine and pharmaceutical company.
Recbio will provide BE with Drug Substance (DS) and transfer technology to formulate, fill, and package vaccines. It will also include technology transfer for DS production at an appropriate time in the future.
According to the agreement, BE will receive the exclusive right to commercialise the vaccine in India and participate in UNICEF & PAHO tenders in other markets.
The HPV9 vaccine is a recombinant vaccine designed to protect against nine types of Human Papillomavirus (HPV), including those responsible for cervical, vulvar, vaginal, anal, and oropharyngeal cancers, as well as genital warts.
Following the signing of the technology license agreement, Recbio has begun transferring the necessary technical knowledge, materials, and expertise to BE to produce the HPV9 vaccine. Recbio will continue to support BE in clinical development and regulatory approvals to ensure a seamless transition. This collaboration comes at a crucial time, as the global demand for cervical cancer prevention is at an all-time high. By leveraging BE’s advanced manufacturing capabilities, this partnership aims to increase the availability of an affordable HPV9 vaccine in India and across international markets.
BE will begin large-scale manufacturing of the HPV9 vaccine once the technology transfer is completed. This collaboration marks a significant milestone for Recbio in entering the Indian and international markets, highlighting its potential in the innovative vaccine field.
